AcelaBio (US) Inc. Achieves Accreditation from the College of American Pathologists (CAP)

SAN DIEGO, September 15, 2022 /PRNewswire/ – AcelaBio (US) Inc., a contract research organization providing histopathology and precision medicine laboratory services for global clinical trials, has been accredited by the College of American Pathologists (CAP). CAP accreditation indicates that the laboratory meets strict requirements for the quality, accuracy and consistency of test results to ensure optimal evaluation of diagnoses and patient outcomes. It also ensures that the laboratory meets the standards of the Clinical Laboratory Improvement Amendments (CLIA), the United States Food and Drug Administration (FDA), and the Occupational Safety and Health Administration (OSHA), as the requirements of the CAP generally exceed these standards. CAP assessment is performed according to discipline-specific checklists that include the latest best practices to ensure the laboratory is keeping up with rapidly changing medicine and laboratory technology.

As a CAP accredited laboratory, AcelaBio has rigorous policies and procedures for test optimization and validation to ensure high quality laboratory testing and patient safety. A documented audit trail is generated for each sample arriving at AcelaBio and tracked through the workflow in a laboratory information system.

“Our mission is to improve the understanding of disease mechanisms and to support the development of safe and effective treatments for patients. Earning accreditation by CAP is recognized internationally as a symbol of quality. This accreditation reinforces the value we bring to our partners and customers by supporting global multicenter clinical trials with histopathology and precision medicine laboratory services,” said Dr. Niels Vande Casteeleassociate professor of medicine, University of California San Diegoand President of AcelaBio.

For more information please contact [email protected].

Related links

www.acelabio.com

About AcelaBio (USA) Inc.

AcelaBio is a state-of-the-art contract research organization that provides end-to-end histopathology and precision medicine laboratory services for pharmaceutical, biotechnology and academic institutions.

AcelaBio provides high-throughput digital pathology services to support multi-center global clinical trials and has the flexibility to develop and validate biomarker assays for new or existing proteins or molecular targets. AcelaBio’s laboratory capabilities apply to a wide range of therapeutic indications, including gastroenterology, oncology and dermatology. AcelaBio is highly specialized in the analysis of gastrointestinal tissues from patients with inflammatory bowel disease (eg, Crohn’s disease and ulcerative colitis), eosinophilic gastrointestinal disease (eg, eosinophilic esophagitis) and liver disease (non-alcoholic steatohepatitis). AcelaBio employs operational, scientific, and medical experts, including US Board-certified pathologists, dedicated to providing reliable, high-quality data and images.

About the College of American Pathologists (CAP)

As the world’s largest organization of board-certified pathologists and a leading provider of laboratory accreditation programs and proficiency testing, the College of American Pathologists (CAP) serves patients, pathologists, and the public in promoting and advocating excellence in the practice of pathology and laboratory medicine. worldwide. For more information, read CAP’s annual report on www.cap.org.

SOURCEAcelaBio

Comments are closed.